Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Exenatide Acetate

Exenatide Acetate

pharmaceutical raw materials
Exenatide Acetate structure

Exenatide Acetate 

structure

Exenatide Acetate Basic Attributes

4244.60796

4244.05000

Characteristics

1812.35000

-2.07850

Exenatide Acetate Use and Manufacturing

Exenatide (i, INN, marketed as Byetta, Bydureon) is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication, belonging to the group of incretin mimetics, approved in April 2005 for the treatment of diabetes mellitus type 2. Exenatide in its Byetta form is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, any time within the 60 minutes before the first and last meal of the day. A once-weekly injection has been approved as of January 27, 2012 under the trademark Bydureon. It is manufactured by Amylin Pharmaceuticals and commercialized by AstraZeneca.

Recommended Suppliers of Exenatide Acetate

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.